Literature DB >> 16603853

Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART.

Beate Kampmann1, Gwen N Tena-Coki, Mark P Nicol, Michael Levin, Brian Eley.   

Abstract

OBJECTIVE: Recent epidemiological studies in adults suggest that HAART can prevent the development of tuberculosis in HIV-infected individuals, but the mechanisms are incompletely understood and no data exist in children. We investigated whether changes in mycobacterial-specific immune responses can be demonstrated in children after commencing antiretroviral therapy.
DESIGN: We measured mycobacterial growth in vitro using a novel whole-blood assay employing reporter-gene tagged bacillus Calmette-Guérin (BCG) in a prospective cohort study in the tuberculosis-endemic environment of South Africa. Key cytokines were measured in supernatants collected from the whole-blood assay using cytometric bead array. PATIENTS: A cohort of 15 BCG-vaccinated HIV-infected children was evaluated prospectively for in-vitro antimycobacterial immune responses before and during the first year of HAART. All children had advanced HIV disease. Nine children completed all study timepoints.
RESULTS: Before HAART, blood from children showed limited ability to restrict the growth of mycobacteria in the functional whole-blood assay. The introduction of HAART was followed by rapid and sustained reconstitution of specific antimycobacterial immune responses, measured as the decreased growth of mycobacteria. IFN-gamma levels in culture supernatants did not reflect this response; however, a decline in TNF-alpha was observed.
CONCLUSION: This is the first study using a functional in-vitro assay to assess the effect of HAART on immune responses to mycobacteria in HIV-infected children. Our in-vitro data mirror the in-vivo observation of decreased susceptibility to tuberculosis in HIV-infected adults receiving antiretroviral agents. This model may be useful for further characterizing immune reconstitution after HAART.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16603853     DOI: 10.1097/01.aids.0000222073.45372.ce

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  27 in total

1.  Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis.

Authors:  Tong Zhu; Sven O Friedrich; Andreas Diacon; Robert S Wallis
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?

Authors:  S D Lawn; A D Harries; B G Williams; R E Chaisson; E Losina; K M De Cock; R Wood
Journal:  Int J Tuberc Lung Dis       Date:  2011-05       Impact factor: 2.373

3.  Pediatric HIV immune reconstitution inflammatory syndrome.

Authors:  David R Boulware; Steven Callens; Savita Pahwa
Journal:  Curr Opin HIV AIDS       Date:  2008-07       Impact factor: 4.283

4.  Scale-up of ART in Malawi has reduced case notification rates in HIV-positive and HIV-negative tuberculosis.

Authors:  H Kanyerere; B Girma; J Mpunga; K Tayler-Smith; A D Harries; A Jahn; F M Chimbwandira
Journal:  Public Health Action       Date:  2016-12-21

Review 5.  Tuberculosis susceptibility and protection in children.

Authors:  Robindra Basu Roy; Elizabeth Whittaker; James A Seddon; Beate Kampmann
Journal:  Lancet Infect Dis       Date:  2018-10-12       Impact factor: 25.071

6.  CAVITATION OF THE GHON FOCUS IN AN HIV-INFECTED INFANT WHO ACQUIRED TUBERCULOSIS AFTER THE INITIATION OF HAART.

Authors:  S Innes; H S Schaaf; M F Cotton
Journal:  South Afr J HIV Med       Date:  2009       Impact factor: 2.744

7.  Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children.

Authors:  Andrew Edmonds; Jean Lusiama; Sonia Napravnik; Faustin Kitetele; Annelies Van Rie; Frieda Behets
Journal:  Int J Epidemiol       Date:  2009-05-15       Impact factor: 7.196

8.  Reduced rate of adverse reactions to the BCG vaccine in children exposed to the vertical transmission of HIV infection and in HIV-infected children from an endemic setting in Brazil.

Authors:  Regina Célia de Souza Campos Fernandes; Luciana Cordeiro de Araújo; Enrique Medina-Acosta
Journal:  Eur J Pediatr       Date:  2008-09-03       Impact factor: 3.183

9.  Incident tuberculosis and risk factors among HIV-infected children in Tanzania.

Authors:  Nan Li; Karim P Manji; Donna Spiegelman; Aisa Muya; Ramadhani S Mwiru; Enju Liu; Guerino Chalamilla; Wafaie W Fawzi; Christopher Duggan
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

Review 10.  [Immune reconstitution inflammatory syndrome (IRIS)].

Authors:  A D Wagner
Journal:  Z Rheumatol       Date:  2008-07       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.